Around 1996, the landscape of HIV treatment underwent a profound transformation with the widespread introduction of antiretroviral combination therapy, often referred to as highly active antiretroviral therapy. Prior to this development, clinical efforts to manage the virus relied primarily on single-drug regimens, which frequently proved insufficient as the virus rapidly developed resistance. By combining multiple classes of antiretroviral agents, clinicians were able to suppress viral replication far more effectively, preventing the virus from mutating and overcoming the medication. This shift in therapeutic strategy marked a turning point in the history of modern medicine, fundamentally altering the prognosis for those living with the virus.

For many individuals with consistent access to healthcare and these new pharmaceutical regimens, the diagnosis of HIV transitioned from a rapidly fatal condition to a long-term, manageable chronic illness. This medical breakthrough significantly reduced mortality rates and improved the quality of life for patients, allowing them to maintain immune function and avoid the most severe complications associated with advanced disease. The success of these therapies necessitated a complete re-evaluation of public health strategies and clinical practices, moving the focus toward long-term care, adherence support, and the prevention of transmission through sustained viral suppression.

The implementation of combination therapy had several far-reaching impacts on the management of the epidemic:

• It enabled the effective suppression of viral replication by targeting the virus at different stages of its life cycle.
• It significantly reduced the emergence of drug-resistant viral strains compared to monotherapy.
• It dramatically lowered the incidence of opportunistic infections and AIDS-related deaths.
• It established a new standard of care that prioritised long-term health outcomes for patients.
• It reshaped the global response to HIV by demonstrating the efficacy of complex, multi-drug treatment protocols.

While the expansion of these therapies offered unprecedented hope, it also highlighted significant disparities in global health equity. The complexity and cost of the new treatment regimens meant that access remained uneven, creating a divide between those in wealthy nations who could readily obtain the medication and those in resource-limited settings. Consequently, the era following 1996 became defined not only by the scientific triumph of combination therapy but also by the ongoing struggle to ensure that these life-saving treatments were accessible to all populations affected by the epidemic.